Anacetrapib + Placebo for anacetrapib
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Heterozygous Familial Hypercholesterolemia (HeFH)
Conditions
Heterozygous Familial Hypercholesterolemia (HeFH)
Trial Timeline
May 1, 2013 → May 1, 2014
NCT ID
NCT01824238About Anacetrapib + Placebo for anacetrapib
Anacetrapib + Placebo for anacetrapib is a phase 3 stage product being developed by Merck for Heterozygous Familial Hypercholesterolemia (HeFH). The current trial status is completed. This product is registered under clinical trial identifier NCT01824238. Target conditions include Heterozygous Familial Hypercholesterolemia (HeFH).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01824238 | Phase 3 | Completed |
| NCT01760460 | Phase 3 | Completed |
Competing Products
18 competing products in Heterozygous Familial Hypercholesterolemia (HeFH)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0780 + Placebo | AstraZeneca | Phase 3 | 77 |
| Enlicitide Decanoate + Placebo | Merck | Phase 2/3 | 65 |
| Inclisiran | Novartis | Phase 3 | 77 |
| Inclisiran + Placebo | Novartis | Phase 3 | 77 |
| Fluvastatin | Novartis | Phase 3 | 77 |
| Inclisiran + Placebo | Novartis | Phase 3 | 77 |
| Evolocumab + Placebo | Amgen | Phase 3 | 76 |
| Bococizumab (PF-04950615;RN316) | Pfizer | Phase 3 | 76 |
| Atorvastatin + Atorvastatin | Pfizer | Phase 1 | 32 |
| IBI306 + placebo | Innovent Biologics | Phase 3 | 76 |
| Lumacaftor Plus Ivacaftor Combination + Ivacaftor | Vertex Pharmaceuticals | Phase 3 | 76 |
| LMT (atorvastatin, simvastatin, or rosuvastatin) + alirocumab + Placebo | Sanofi | Phase 3 | 76 |
| Placebo + Alirocumab | Sanofi | Phase 3 | 76 |
| Praluent | Sanofi | Approved | 84 |
| AK102 + Placebo + Statins and/or Ezetimibe | Akeso | Phase 2 | 51 |
| lerodalcibep | Medpace | Phase 3 | 74 |
| mipomersen sodium + placebo | Ionis Pharmaceuticals | Phase 3 | 74 |
| MGL-3196 (resmetirom) + Placebo | Madrigal Pharmaceuticals | Phase 2 | 49 |